Scoping review of nutrigenomic-guided nutraceuticals and aging biomarkers in adults
A scoping review of 21 human studies found mostly favorable effects of nutrigenomic-guided nutraceuticals on intermediate molecular markers, but little direct evidence that validated biological-aging biomarkers such as epigenetic clocks or telomere dynamics are slowed. [1]
Automatic summary · not editorially reviewed
The key findings
The scoping review included 21 human studies of personalized nutraceutical interventions guided by molecular data in adults aged 18 or older. [1]
Most included studies showed favorable effects on intermediate molecular biomarkers, not on validated biological-aging outcomes. [1]
Direct evidence that validated biomarkers such as epigenetic clocks or telomere dynamics show slowed biological aging remains limited. [1]
The source at a glance
- Study type / format
- Scoping review of human studies (abstract only)
- Population / context
- Adults aged 18 or older receiving personalized nutraceutical interventions informed by genetic, genomic, metabolomic or other molecular data
- Summary based on
- Study abstract
- Original publication
- August 23, 2026
Mapping personalized nutraceutical evidence in adults
The review asked how much human evidence exists on personalized nutraceutical interventions guided by genetic, genomic, metabolomic or other molecular data, and how these affect biomarkers linked to biological aging. It followed Joanna Briggs Institute methodology and PRISMA-ScR guidelines and searched four databases for studies published between 2021 and 2026. Eligible studies enrolled adults aged 18 or older.
Supporting source [1]
Intermediate markers improved; aging clocks rarely tested
Twenty-one studies were included, covering omega-3 fatty acids, polyphenols, Nigella sativa, vitamin D, methyl-donor micronutrients, fermented papaya preparation and other nutraceutical or functional-food interventions. Four themes emerged: multi-omic stratification, biological aging biomarkers, redox-inflammatory modulation and applications in metabolic disorders. Most studies showed favorable effects on intermediate molecular biomarkers such as inflammatory cytokines, oxidative stress markers, lipid metabolism, endothelial function and DNA methylation signatures.
Supporting source [1]
Limited direct evidence on validated aging biomarkers
The authors conclude that personalized nutraceuticals are biologically plausible for modulating pathways associated with healthy aging. However, evidence directly showing slowed biological aging through validated biomarkers such as epigenetic clocks or telomere dynamics remains limited. They call for robust longitudinal studies with validated biological-aging biomarkers and clinically meaningful outcomes before widespread use in precision medicine.
Supporting source [1]
How to interpret this
This explainer is based only on the abstract; the full text was not reviewed. The abstract reports a scoping review of 21 studies but gives no individual study designs, sample sizes, follow-up durations or effect sizes, and it does not quantify the intermediate biomarker changes.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Llanos-Díaz AV, Apolaya-Segura M, Sevillano OR, Marín-Sanchez O, Osores JJV, Carrasco AGM, Llanos-Diaz SN, Diaz-Obregón DZ. · europepmc.org · August 23, 2026